NewCardio Board of Directors Elects Patrick Maguire Chairman
SANTA CLARA, Calif., June 23, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology provider, announced today that Patrick Maguire, MD, PhD, member of the NewCardio board of directors since March of 2008 and a proven leader and a seasoned executive with experience in a variety of leadership roles with companies involved in medical devices and pharmaceuticals, has been elected Chairman of NewCardio's Board of Directors, effective immediately. Mark W. Kroll, PhD, FACC, FHRS, NewCardio's previous chairman, will remain a director.
Dr. Maguire has served as the Chief Executive Officer and President of CyberHeart Inc. since 2006. He joined CyberHeart following the acquisition of the oncology assets of Targent Incorporated, where Dr. Maguire served as President, CEO, and Director since 2002. Prior to joining Targent, Dr. Maguire was Vice President of Medical Affairs and Technology Development at VitaGen Incorporated, where he oversaw the preparation of IND's, NDA's, and IDE's and managed VitaGen's clinical trials in acute and chronic liver failure as well as medical and industry collaborations. He is a cardiovascular and thoracic surgeon and has acted as a principal investigator for medical devices and associated clinical trials. Dr. Maguire is a fellow of the American and Royal College of Surgeons and a member of more than 20 medical, academic and business societies. He received an AB degree from Wesleyan University, an MD and PhD (Physiology and Biophysics) degrees from Georgetown University and an MBA degree from Pepperdine University. He completed surgical and cardiovascular fellowships at The Peter Bent Brigham Hospital, Harvard University, and Stanford University.
Dr. Maguire commented, "